Redetermination of rifampicin penta-hydrate revealing a zwitterionic form of the anti-biotic

Acta Crystallographica Section C: Crystal Structure Communications

Volumn 68, Issue 5, 2012, Pages

  Wicher, Barbara ^a   Pyta, Krystian ^a   Przybylski, Piotr ^a   Tykarska, Ewa ^b   Gdaniec, Maria ^a  

^a ADAM MICKIEWICZ UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE GROUPS; HELICAL CHAINS; ISOSTRUCTURAL; OH GROUP; ZWITTERIONIC FORMS;

AMIDES; CRYSTAL STRUCTURE; HYDRATES; HYDRATION; METHANOL; PHENOLS;

HYDROGEN BONDS;

TETRA;

ANTIINFECTIVE AGENT; RIFAMPICIN;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; HYDROGEN BOND; X RAY CRYSTALLOGRAPHY;

ANTI-BACTERIAL AGENTS; CRYSTALLOGRAPHY, X-RAY; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RIFAMPIN;

EID: 84860518681     PISSN: 01082701     EISSN: 16005759     Source Type: Journal    
DOI: 10.1107/S0108270112015296     Document Type: Article

References (18)

1. Agilent (2010). CrysAlis PRO. Agilent, Yarnton, Oxfordshire, England.
2. Agrawal, S., Ashokraj, Y., Bharatam, P. V., Pillai, O. & Panchagnula, R. (2004). Eur. J. Pharm. Sci. 22, 127-144.
3. Bacchi, A., Pelizzi, G., Nebuloni, M. & Ferrari, P. (1998). J. Med. Chem. 41, 2319-2332.
4. Baysarowich, J., Koteva, K., Hughes, D. W., Ejim, L., Griffiths, E., Zhang, K., Junop, M. & Wright, G. D. (2008). Proc. Natl Acad. Sci. USA, 105, 4886-4891.
5. Burla, M. C., Caliandro, R., Camalli, M., Carrozzini, B., Cascarano, G. L., De Caro, L., Giacovazzo, C., Polidori, G. & Spagna, R. (2005). J. Appl. Cryst. 38, 381-388.
6. Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A. & Darst, S. A. (2001). Cell, 104, 901-912.
7. Chrencik, J. E., Orans, J., Moore, L. B., Xue, Y., Peng, L., Collins, J. L., Wisely, G. B., Lambert, M. H., Kliewer, S. A. & Redinbo, M. R. (2005). Mol. Endocrinol. 19, 1125-1134.
8. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486-501.
9. Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.
10. Ferrari, P. & Gallo, G. G. (1975). Il Farmaco, 30, 676-696.
11. Floss, H. G. & Yu, T.-W. (2005). Chem. Rev. 105, 621-632.
12. Gadret, M., Goursolle, M., Leger, J. M. & Colleter, J. C. (1975). Acta Cryst. B31, 1454-1462.
13. Henwood, S. Q., Liebenberg,W., Tiedt, L. R., Lötter, A. P. & de Villiers,M. M. (2001). Drug Dev. Ind. Pharm. 27, 1017-1029.
14. Macrae, C. F., Edgington, P. R., McCabe, P., Pidcock, E., Shields, G. P., Taylor, R., Towler, M. & van de Streek, J. (2006). J. Appl. Cryst. 39, 453-457.
15. Pelizza, G., Nebuloni, M., Ferrari, P. & Gallo, G. G. (1977). Il Farmaco, 32, 471-481.
16. Pyta, K., Przybylski, P., Wicher, B., Gdaniec, M. & Stefańska, J. (2012). Org. Biomol. Chem. 12, 2385-2388.
17. Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
18. Villiers, M. M. de, Caira, M. R., Li, J., Strydom, S. J., Bourne, S. A. & Liebenberg, W. (2011). Mol. Pharm. 8, 877-888.